Investing.comCodex · 实盘不做把握 3/10
北京时间·🕒 发布 19:36:43时区推断·⟳ 抓取 19:37:52·⚡ 决策 07-28 19:46:23 +8m31s·91.0 天前
Nasus Pharma 任命 Brendan O’Grady 为新任 CEO
本次只是临床阶段药企的管理层任命，未披露融资、合作、临床数据、监管进展或商业化金额。
📄 原文Investing.com↗ 原文
Nasus Pharma names Brendan O’Grady as new CEO
Oil extends slide as U.S.-Iran talks raise hopes of lasting de-escalation TEL AVIV, Israel - Nasus Pharma Ltd. (NYSE:NS…
不做 Nasus Pharma（NSRX.US）
普通管理层任命，未披露临床数据、审批进展、订单或融资等可量化增量，方向和短线 edge 不足，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-28 · 扩散 low · price-in 风险 medium ↗
关键理由
- 本次只是临床阶段药企的管理层任命，未披露融资、合作、临床数据、监管进展或商业化金额。
主要风险
- NS002 关键读数仍在 2027 年一季度，当前 CEO 更替本身不足以形成短线可回测交易边界。
原文全文
展开原文 · 2,088 字
Oil extends slide as U.S.-Iran talks raise hopes of lasting de-escalation
TEL AVIV, Israel - Nasus Pharma Ltd. (NYSE:NSRX) announced Monday the appointment of Brendan P. O’Grady as Chief Executive Officer, effective July 27, 2026. O’Grady replaces Dan Teleman in the role.
The clinical-stage pharmaceutical company said O’Grady will focus on the commercial development of NS002, the company’s lead product candidate being developed as an intranasal epinephrine treatment for Type I allergic reactions, including anaphylaxis. He will also oversee advancement of the company’s pipeline and its NasaX intranasal technology platform, according to a press release statement.
O’Grady brings more than 30 years of pharmaceutical industry experience to the position. He spent 21 years at Teva Pharmaceuticals, where he served as CEO of Teva USA and Executive Vice President of North America Commercial. He previously served as Chief Executive Officer of Assertio Holdings (NASDAQ:ASRT). Investors tracking Nasus Pharma’s progress through this leadership transition can access comprehensive financial metrics, valuation analysis, and expert insights on InvestingPro, which provides detailed health scores and performance data for clinical-stage pharmaceutical companies.
Udi Gilboa, Chairman of the Board of Directors, said the appointment positions the company for its next phase of growth as NS002 advances toward a pivotal trial planned for the fourth quarter of 2026, with topline data expected in the first quarter of 2027.
O’Grady holds a Bachelor of Science degree in Management Science from SUNY Geneseo and a Master of Business Administration from Baker University’s School of Professional and Graduate Studies.
The company said it will provide additional information regarding the appointment in a Report on Form 6-K filed with the U.S. Securities and Exchange Commission.
Nasus Pharma develops intranasal therapies using its proprietary intranasal powder technology platform.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
TEL AVIV, Israel - Nasus Pharma Ltd. (NYSE:NSRX) announced Monday the appointment of Brendan P. O’Grady as Chief Executive Officer, effective July 27, 2026. O’Grady replaces Dan Teleman in the role.
The clinical-stage pharmaceutical company said O’Grady will focus on the commercial development of NS002, the company’s lead product candidate being developed as an intranasal epinephrine treatment for Type I allergic reactions, including anaphylaxis. He will also oversee advancement of the company’s pipeline and its NasaX intranasal technology platform, according to a press release statement.
O’Grady brings more than 30 years of pharmaceutical industry experience to the position. He spent 21 years at Teva Pharmaceuticals, where he served as CEO of Teva USA and Executive Vice President of North America Commercial. He previously served as Chief Executive Officer of Assertio Holdings (NASDAQ:ASRT). Investors tracking Nasus Pharma’s progress through this leadership transition can access comprehensive financial metrics, valuation analysis, and expert insights on InvestingPro, which provides detailed health scores and performance data for clinical-stage pharmaceutical companies.
Udi Gilboa, Chairman of the Board of Directors, said the appointment positions the company for its next phase of growth as NS002 advances toward a pivotal trial planned for the fourth quarter of 2026, with topline data expected in the first quarter of 2027.
O’Grady holds a Bachelor of Science degree in Management Science from SUNY Geneseo and a Master of Business Administration from Baker University’s School of Professional and Graduate Studies.
The company said it will provide additional information regarding the appointment in a Report on Form 6-K filed with the U.S. Securities and Exchange Commission.
Nasus Pharma develops intranasal therapies using its proprietary intranasal powder technology platform.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。